RECRUITING

Multidimensional Predictive Modeling to Understand Mechanisms of Exercise Response Heterogeneity in Older Adults (M3AX)

Conditions

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Aging-related functional declines are thought to be caused by hallmark biological processes that ultimately manifest in physical, mental, and metabolic impairments that compromise healthspan and quality of life. Exercise is a multipotent treatment with promise to mitigate most aging hallmarks, but there is substantial variability in exercisƒe responsiveness. Combining endurance and resistance training in alignment with public health guidelines will be used to better understand variable exercise responsiveness in older adults with the ultimate goal of improving each older adult's capacity to attain the many health benefits of exercise.

Official Title

Multidimensional Predictive Modeling to Understand Mechanisms of Exercise Response Heterogeneity in Older Adults

Quick Facts

Study Start:2024-09-15
Study Completion:2029-07-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06507189

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:60 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Male or female aged 60 or above
  2. 2. Free of chronic disease
  3. 3. No structured exercise program (2 or more bouts/wk) within previous 12 months
  4. 4. Cognitively capable of providing informed consent
  1. 1. Neuromuscular or musculoskeletal disorder that would limit ability to perform the exercise and/or testing bouts
  2. 2. Cardiopulmonary disorders or reduced breathing capacity (FEV1 \< 80% expected)
  3. 3. Metabolic diseases including markers of liver disease (ALT \> 52 U/l) and type 2 diabetes (HbA1C ≥ 6.5, fasting blood glucose ≥ 126 mg/dl)
  4. 4. Any other disease or disorder that would influence exercise response (e.g., chronic kidney disease, dementia, current cancer diagnosis or within 2 yr remission, cerebrovascular disease)
  5. 5. Any current infectious disease
  6. 6. Life expectancy \< 1 year
  7. 7. Insulin sensitizing/blood glucose lowering agents such as metformin
  8. 8. High dose lipophilic statin (≥40 mg/d)
  9. 9. Lidocaine allergy
  10. 10. Regular tobacco use and/or vaping
  11. 11. Excessive alcohol consumption (3 drinks/d or 7 drinks/wk for females; 4 drinks/d or 14 drinks/wk for males)
  12. 12. BMI ≥ 30.0 kg/m2
  13. 13. Unable to commit to \~6 months required to complete the study

Contacts and Locations

Study Contact

Craig Tuggle
CONTACT
205-352-6036
ctuggle@ihmc.org
Marcas Bamman, PHD
CONTACT
mbamman@ihmc.org

Principal Investigator

Marcas Bamman
PRINCIPAL_INVESTIGATOR
Florida Institute for Human and Machine Cognition

Study Locations (Sites)

Florida Institute for Human and Machine Cognition
Pensacola, Florida, 32502
United States
Oklahoma Medical Research Foundation
Oklahoma City, Oklahoma, 73104
United States

Collaborators and Investigators

Sponsor: Florida Institute for Human and Machine Cognition

  • Marcas Bamman, PRINCIPAL_INVESTIGATOR, Florida Institute for Human and Machine Cognition

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-09-15
Study Completion Date2029-07-01

Study Record Updates

Study Start Date2024-09-15
Study Completion Date2029-07-01

Terms related to this study

Additional Relevant MeSH Terms

  • Sarcopenia